Glenmark Pharmaceuticals Inc., USA Sustainability Profile
Glenmark Pharmaceuticals Inc., USA, is a prominent player in the global pharmaceutical industry, headquartered in the United States. Founded in 2001, the company has established a strong presence in key operational regions, including North America and Europe, focusing on the development and manufacturing of innovative medicines. Specialising in a diverse range of therapeutic areas such as dermatology, respiratory, and oncology, Glenmark is recognised for its commitment to research and development, which has led to the introduction of unique generic and specialty pharmaceuticals. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of new therapies, solidifying its market position as a trusted provider of high-quality healthcare solutions.
DitchCarbon Score
How does Glenmark Pharmaceuticals Inc., USA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glenmark Pharmaceuticals Inc., USA's score of 75 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glenmark Pharmaceuticals Inc., USA, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Glenmark Pharmaceuticals Limited, which may influence its climate commitments and initiatives. While no specific reduction targets or achievements are documented for Glenmark Pharmaceuticals Inc., USA, it is important to note that any climate commitments or initiatives may be inherited from its parent company, Glenmark Pharmaceuticals Limited. This includes potential targets set under the Science Based Targets initiative (SBTi) and disclosures made to the Carbon Disclosure Project (CDP), both of which are cascaded from the parent organisation. As a part of the pharmaceutical industry, Glenmark Pharmaceuticals Inc., USA is likely to align with broader sectoral goals aimed at reducing carbon footprints and enhancing sustainability practices. However, without specific data or commitments outlined for this subsidiary, the details remain vague. In summary, Glenmark Pharmaceuticals Inc., USA is currently without specific emissions data or reduction targets, relying on the climate initiatives and commitments of its parent company, Glenmark Pharmaceuticals Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 11,713,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,231,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,277,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Glenmark Pharmaceuticals Inc., USA's Industry?
How Carbon Intensive is Glenmark Pharmaceuticals Inc., USA's Location?
Glenmark Pharmaceuticals Inc., USA's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Glenmark Pharmaceuticals Inc., USA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
